IMBRUVICA® (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström’s Macroglobulinemia and Relapsed/Refractory Marginal Zone Lymphoma and currently being evaluated in multiple types of cancer and for other serious diseases.

Type of Molecule

Small Molecule

Target

BTK

Region

US, EU

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Diffuse Large B-cell Lymphoma (DLBCL) New Indication Phase 3
Follicular Lymphoma (FL) New Indication Phase 3
Relapsed/Refractory Marginal Zone Lymphoma (MZL) New Indication Phase Approved Approved
Acute Myeloid Leukemia (AML) New Indication Phase 2
Multiple Myeloma (MM) New Indication Phase 2
Pancreatic Cancer New Indication Phase 3
Solid Tumors New Indication Phase 2
Chronic Graft versus Host Disease (cGVHD) New Indication Phase Approved Approved